A Case-Control Study of Cognitive Function in Patients with End-Stage Renal Disease Before and After Hemodialysis in Southern Spain

María Mar Sánchez-Fernández; María José Fernández-Serrano; Antonio S. Moreno-Salazar; Pedro L. Quirós-Ganga; Gustavo A. Reyes del Paso

doi:10.12659/MSM.940409

19 June 2023 : Clinical Research

A Case-Control Study of Cognitive Function in Patients with End-Stage Renal Disease Before and After Hemodialysis in Southern Spain

María Mar Sánchez-Fernández^1ABCDEF*, María José Fernández-Serrano^2ACDEFG, Antonio S. Moreno-Salazar^3ADEF, Pedro L. Quirós-Ganga^4ABDEF, Gustavo A. Reyes del Paso

^5ACDEF

DOI: 10.12659/MSM.940409

Med Sci Monit 2023; 29:e940409

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 2 Mean (±SD) of cognitive variables for the 2 groups during the pre-hemodialysis evaluation.

Domain	Test	Dep. Var.	Group	Mean±SD	F (1,79)	p	ηp2
Visual memory	Rey-Osterrieth complex figure (ROCF)	Copy execution	ESRD-HD	33.05±3.38	1.17	0.283	0.015
		Copy execution	Hp	33.90±2.16	1.17	0.283	0.015
		Memory execution	ESRD-HD	16.85±6.14	2.46	0.121	0.030
		Memory execution	HP	19.01±4.71	2.46	0.121	0.030
Verbal memory	Verbal learning test Spain-Complutense (TAVEC)	RLCP	ESRD-HD	9.12±3.16	9.29	0.003	0.105
		RLCP	HP	11.12±2.71	9.29	0.003	0.105
		RLLP	ESRD-HD	9.47±2.98	13.76	<0.001	0.148
		RLLP	HP	11.86±2.67	13.76	<0.001	0.148
		RIAT	ESRD-HD	46.65±8.45	16.26	<0.001	0.171
		RIAT	HP	54.43±8.17	16.26	<0.001	0.171
		Discriminability	ESRD-HD	91.61±5.57	1.68	0.198	0.021
		Discriminability	HP	93.57±6.51	1.68	0.198	0.021
Sustained and selective attention	D2	TCA	ESRD-HD	125.12±34.73	5.36	0.023	0.063
		TCA	HP	144.17±36.09	5.36	0.023	0.063
		TOT	ESRD-HD	318.14±79.57	7.65	0.007	0.088
		TOT	HP	365.74±82.47	7.65	0.007	0.088
		CON	ESRD-HD	122.14±36.65	5.87	0.018	0.069
		CON	HP	142.88±36.61	5.87	0.018	0.069
Processing speed	Trail Making Test A (TMT-A)	C2	ESRD-HD	46.77±18.94	8.24	0.005	0.094
		C2	HP	38.48±13.37	8.24	0.005	0.094
		C3	ESRD-HD	58.74±29.66	8.42	0.005	0.096
		C3	HP	41.86±16.49	8.42	0.005	0.096
	Stroop	C1	ESRD-HD	33.95±6.73	14.70	<0.001	0.157
		C1	HP	29.36±4.77	14.70	<0.001	0.157
		C2	ESRD-HD	23.60±5.54	14.63	<0.001	0.156
		C2	HP	20.31±2.97	14.63	<0.001	0.156
	Five Digit Test (5DT)	C1	ESRD-HD	20.93±3.92	7.79	0.007	0.090
		C1	HP	18.71±3.72	7.79	0.007	0.090
		C2	ESRD-HD	23.00±4.24	6.49	0.013	0.076
		C2	HP	21.17±3.72	6.49	0.013	0.076
	D2	TR	ESRD-HD	339.95±80.75	7.09	0.009	0.082
	D2	TR	HP	384.29±80.59	7.09	0.009	0.082
Results of group comparisons are also included. SD – standard deviation; ESRD HD – end-stage renal disease patients treated with hemodialysis; HP – healthy participants.

Back to the Article

A Case-Control Study of Cognitive Function in Patients with End-Stage Renal Disease Before and After Hemodialysis in Southern Spain

Your Privacy